Study of Apatinib in Patients With Differentiated Thyroid Cancer

Sponsor
Peking Union Medical College Hospital
Study ID
NCT02731352
Phase
PHASE2
Status
Completed

Conditions

  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
  • Apatinib — DRUG
    Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.

Study Details

The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer

Key Dates

Start date
Mar 11, 2016
Status verified
Aug 2021
Primary completion
Feb 27, 2020
Completion
Feb 28, 2021

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: iodine-131 Refractory/Resistant Differentiated Thyroid Cancer
    iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer

Primary Outcome Measure

Disease control rate (DCR) [ Time Frame: An expected average of 8 weeks ]

Related Studies